|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors显示文摘The recent discovery of immune checkpoints inhibitors, especially anti-programmed cell death protein 1(PD-1)and anti-programmed cell death protein ligand 1(PD-L1) monoclonal antibodies, has opened new scenarios in the management of non-small cell lung cancer(NSCLC) and this new class of drugs has achieved a rapid development in the treatment of this disease. However, considering the costs of these drugs and the fact that only a subset of patients experience long-term disease control, the identification of predictive biomarkers for the selection of candidates suitable for treatment has become a priority. The research focused mainly on the expression of the PD-L1 receptor on both tumor cells and/or immune infiltrates determined by immunohistochemistry(IHC). However, different checkpoint inhibitors were tested, different IHC assays were used, different targets were considered(tumor cells, immune infiltrates or both) and different expression thresholds were employed in clinical trials. In some trials the assay was used prospectively to select the patients, while in other trials it was evaluated retrospectively. Some confusion emerges, which makes it difficult to easily compare the literature data and to translate them in practice management. This mini-review shows the possibilities and pitfalls of the PD-L1 expression to predict the activity and efficacy of anti PD1/PD-L1 monoclonal antibodies in the treatment of NSCLC. | Carmelo Tibaldi Alice Lunghi Editta Baldini | 2017 | World Journal of Clinical Oncology2017，8，4： | 8 |
| 2 | Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review显示文摘Despite advances in the management of patients with locally advanced,non-metastatic rectal adenocarcinoma(LARC),prognosis remains largely unsatisfactory due to a high rate of distant relapse.In fact,currently available neoadjuvant protocols,represented by fluoropyrimidine-based chemo-radiotherapy(CT-RT)or short-course RT,together with improved surgical techniques,have largely reduced the risk of local relapse,with limited impact on distant recurrence.Available results of phaseⅢtrials with additional cytotoxic agents combined with standard CT-RT are disappointing,as no significant reduction in the risk of recurrence has been demonstrated.In order to improve the control of micrometastatic disease,integrating targeted agents into neoadjuvant treatment protocols thus offers a rational approach.In particular,the antiangiogenic agent bevacizumab has demonstrated synergistic activity with both CT and RT in pre-clinical and clinical models,and thusmay represent a suitable companion in the neoadjuvant treatment of LARC.Preliminary results of phase?Ⅰ-Ⅱclinical studies are promising and suggest potential clinical parameters and molecular predictive biomarkers useful for patient selection:treatment personalization is indeed the key in order to maximize the benefit while reducing the risk of more complex neoadjuvant treatment schedules. | Lorenzo Fornaro Chiara Caparello Caterina Vivaldi Virginia Rotella Gianna Musettini Alfredo Falcone Editta Baldini Gianluca Masi | 2014 | World Journal of Gastroenterology2014，20，20： | 5 |
| 3 | Combination chemotherapy with vinorelbine,ifosfamide and cisplatin: a phase Ⅱ study in stageⅢb-Ⅳ non-small cell lung cancer显示文摘 | Editta B Carmelo T Antonio C | 1994 | Semin Oncol1994，21，3： | 1 |
| 4 | Combionation chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase Ⅱ study in stage Ⅲ b-Ⅳ non-small-cell lung cancer(NSCLC) 显示文摘 | Carmelo T Antonio C | 1994 | Semin Oncol1994，21，3： | 1 |
| 5 | Long-term results of combined-modality therapy for inflammatory breast carcinoma 显示文摘 | Editta B Giovanni G Giuseppe E | 2004 | Clinical Breast Cancer2004，5，5： | 1 |
| 6 | Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy显示文摘 | Lorenzo Fornaro Caterina Vivaldi Chiara Caparello Rodolfo Sacco Virginia Rotella Gianna Musettini Sauro Luchi Edi Editta Baldini Alfredo Falcone Gianluca Masi | 2014 | Future Oncol2014，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员